Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...

The deal comes as GSK, led by chief exec Emma Walmsley (pictured) focuses on growing its pipeline to offset declining ...

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD <li /> Additional ...

Hengrui Pharmaceuticals has licensed global rights to its HRS-9821 program and granted GSK options on up to 11 additional candidates, excluding Greater China. GSK will pay USD 500 million upfront, ...